 - Patients in intermediate risk group, with normal karyotype, a single course of induction chemotherapy to achieve the CR, the absence of adverse molecular features FLT3-ITD or MLL-PTD and low minimal residual disease levels after consolidation MRD0,1 receive an autologous PBSC transplant, regardless of having an HLA-identical sibling. 